BMRN icon

BioMarin Pharmaceuticals

58.10 USD
-0.72
1.22%
At close Jul 11, 4:00 PM EDT
After hours
58.25
+0.15
0.26%
1 day
-1.22%
5 days
1.98%
1 month
1.64%
3 months
2.25%
6 months
-13.27%
Year to date
-12.62%
1 year
-30.76%
5 years
-53.30%
10 years
-59.79%
 

About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Employees: 3,040

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

84% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 55

39% more repeat investments, than reductions

Existing positions increased: 239 | Existing positions reduced: 172

11% more call options, than puts

Call options by funds: $97.7M | Put options by funds: $87.7M

8% more funds holding

Funds holding: 534 [Q4 2024] → 575 (+41) [Q1 2025]

6% more capital invested

Capital invested by funds: $12B [Q4 2024] → $12.8B (+$776M) [Q1 2025]

0.41% less ownership

Funds ownership: 96.11% [Q4 2024] → 95.71% (-0.41%) [Q1 2025]

14% less funds holding in top 10

Funds holding in top 10: 7 [Q4 2024] → 6 (-1) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$78
34%
upside
Avg. target
$91
57%
upside
High target
$104
79%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Goldman Sachs
Salveen Richter
79%upside
$104
Buy
Maintained
5 May 2025
Citigroup
David Lebovitz
34%upside
$78
Neutral
Maintained
2 May 2025

Financial journalist opinion

Based on 8 articles about BMRN published over the past 30 days

Positive
Zacks Investment Research
21 hours ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock
Positive
Zacks Investment Research
1 day ago
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report?
Positive
Zacks Investment Research
3 days ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock
Positive
CNBC Television
4 days ago
It is time for a move higher in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.
It is time for a move higher in biotech, says Mizuho's Jared Holz
Neutral
PRNewsWire
1 week ago
BioMarin Announces Completion of Acquisition of Inozyme
SAN RAFAEL, Calif. , July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million.
BioMarin Announces Completion of Acquisition of Inozyme
Positive
Zacks Investment Research
2 weeks ago
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Positive
Zacks Investment Research
2 weeks ago
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Neutral
PRNewsWire
2 weeks ago
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis No new safety signals observed SAN RAFAEL, Calif. , June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN ® (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C.
BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress
Positive
The Motley Fool
1 month ago
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high.
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
Positive
Finbold
1 month ago
2 top value stocks to buy for second half of 2025
The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.
2 top value stocks to buy for second half of 2025
Charts implemented using Lightweight Charts™